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Abstract: The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) proteins 
are a family of ubiquitously expressed transcription factors that regulate the response to cellular 
stress. They mediate innate and adaptive immunity through the initiation of an inflammatory 
response to pro-inflammatory signals. The role of persistent inflammation in aiding tumor 
development has led to the NF-κB family of transcription factors being strongly implicated 
in promoting cancer. However, recent studies have now revealed that NF-κB can also func-
tion as a tumor suppressor through the induction of cellular senescence. Cellular senescence 
is a stable cell cycle arrest that normal cells undergo in response to a variety of intrinsic and 
extrinsic stimuli including: progressive telomere shortening, changes in telomeric structure, or 
other forms of genotoxic stress. Senescence can compromise tissue repair and regeneration, 
contributing to tissue and organismal aging via the accumulation of senescent cells, depletion 
of stem/progenitor cells and secretion of an array of inflammatory cytokines, chemokines, and 
matrix metalloproteinases. Senescence can also lead to the removal of potentially cancerous 
cells, thereby acting as a potent tumor suppressor mechanism. Herein, we review the evidence 
indicating a role for NF-κB in tumor suppression via cellular senescence and suggest that 
depending upon the subunit expressed, the biological context, and the type and intensity of the 
signal, NF-κB can indeed promote senescence growth arrest.
Keywords: cell senescence, growth arrest, NF-κB, SASP
Introduction to NF-κB
The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) family 
of transcription factors have been extensively studied over the last 25 years since they 
were discovered by binding to the immunoglobulin κ light chain gene enhancer (iκE).1 
They comprise five family members: RELA (p65), RELB, c-REL, p105/p50 (NF-κB1), 
and p100/p52 (NF-κB2), which all share the Rel homology domain, permitting their 
dimerization and translocation to the nucleus.2,3 RELA, RELB, and c-REL also have a 
transactivation domain, whilst p105/p50 and p100/p52 contain ankyrin repeat domains 
(Figure 1). The primary mediator of NF-κB transcriptional activity in response to 
activators such as inflammatory cytokines and Toll-like receptor (TLR) signaling, 
is the RELA:p50 heterodimer, whereas other subunits have a more primary role in 
other contexts. The RELA:p50 heterodimer is the most readily detectable form of 
this complex.2,3
The mechanism of action underlying the activation of NF-κB, falls into two broad 
categories: a canonical pathway and a non-canonical pathway (Figure 2). In the canoni-
cal pathway, NF-κB homo-and heterodimers are bound to inhibitors of NF-κB (IκB) 
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Figure 2 Canonical and non-canonical pathways of NF-κB activation.
Notes: in the canonical pathway, a variety of inputs such as inflammatory cytokines induce the phosphorylation and activation of the IκB kinase (iKK) complex (iKKα, iKKβ, 
and iKKγ/NeMO). This phosphorylates iκB leading to its ubiquitination and degradation by the 26S proteasome leading to nuclear translocation of ReLA:p50 dimers. The 
non-canonical pathway is activated by more specific inputs such as lymphotoxin-β and leads to NF-κB inducing kinase (NiK) phosphorylating and activating iKKα, a member 
of the multi-subunit iκB kinase complex. This leads to phosphorylation and subsequent ubiquitination of p100 resulting in its processing by the proteosome to produce 
transcriptionally active ReLB:p52 dimers.
Abbreviations: NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; ReL, reticuloendotheliosis virus; RiP, receptor-interacting serine/threonine protein 
kinase 1; TAB, transforming growth factor-beta activated kinase binding protein; TAK, transforming growth factor-beta activated kinase; Ub, ubiquitin.
in unstimulated cells, leading to them being retained in the 
cytosol.2 A variety of stimuli can induce the phosphorylation 
of IκB by the multi-subunit IκB kinase complex (IKKα, 
IKKβ, and IKKγ/NEMO), leading to ubiquitination and 
subsequent degradation of IκB by the 26S proteasome.2,4 
This unmasks a nuclear localization signal, resulting in the 
nuclear translocation of NF-κB dimers and activation of a 
plethora of target genes. The canonical pathway is vital for 
the activation of innate immunity and inflammation.2
In response to stimuli such as lymphotoxin β, an alternative 
non-canonical pathway is activated. This involves the NF-κB 
inducing kinase (NIK), which phosphorylates and activates 
IKKα, leading to the proteosomal processing of p100 with 
preferential nuclear translocation of RELB:p52 dimers.5,6 
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Figure 1 NF-κB protein family.
Notes: All family members share the RHD, composed of a DNA-binding region and a dimerization region. ReLA and c-ReL have two TAD whereas ReLB contains only one. 
P100 and p105 precursor proteins are processed by the proteosome to the mature p52 and p50 respectively and lack a transactivation domain. Other indicated domains 
are: LZ; GRR; DD.
Abbreviations: DD, death domain; DNA, deoxyribonucleic acid; GRR, glycine-rich region; LZ, leucine zipper; NF-κB, nuclear factor kappa-light-chain-enhancer of activated 
B cells; RHD, Rel homology domain; TAD, transactivation domains.
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Although the canonical and non-canonical pathways have 
separate regulatory mechanisms, recent evidence suggests 
that crosstalk between these pathways is vital for NF-κB 
activation, as synthesis of RELB is controlled by RELA 
signaling.7,8
Physiological role of NF-κB
NF-κB mediates the cellular response to stimuli such as 
cytokines, free radicals, deoxyribonucleic acid (DNA) 
damage, oxidized low density lipoproteins, and bacterial or 
viral antigens, most of which are induced upon intrinsic or 
extrinsic cellular stress.9,10 It does this by binding to specific 
DNA sequences within target genes in the nucleus and can 
act as a transcriptional activator or repressor.11 This family 
of transcription factors (TFs) also has an important role in 
the development of the skeletal system and epithelium.12,13 
They are required for proper organogenesis of several 
epithelial tissues such as the mammary gland; blockage of 
NF-κB activity in the mammary gland of mice leads to a 
severe lactation deficiency.14 Similarly, activation of NF-κB 
in axon-associated Schwann cells is essential for progression 
to a myelinating phenotype.15 However, as NF-κB proteins 
were first identified as factors that regulate B-lymphocyte-
specific transcription, the role of NF-κB in the development, 
specialization, and maintenance of the immune system is 
more thoroughly documented.16–18 Hemopoiesis is character-
ized by apoptosis, differentiation, and proliferation, which 
are key processes controlled by the action of NF-κB. During 
hemopoiesis, cells of the lymphoid and myeloid lineages 
such as T cells, B cells, monocytes, macrophages, dendritic 
cells, natural killer cells, basophils, eosinophils, neutro-
phils, and mast cells are all formed. NF-κB contributes to 
hemopoiesis by promoting the survival and differentiation 
of precursors to a particular cell fate, throughout all stages 
of this process.19 These cells are important for both innate 
and adaptive immunity and can initiate an inflammatory 
response to pro-inflammatory signals such as cytokines and 
chemokines, many of which are transcriptionally activated 
by NF-κB.20
NF-κB also has an important role in normal B- cell matu-
ration as purified B cells from p50/NF-kappa B knockout 
(p50−/−) mice have a reduced ability to mature to Ig secre-
tion, germ-line CH gene activation, and undergo Ig class 
switching, as well as mitogenesis.18
As a result, deregulation or dysfunction of NF-κB 
is detrimental to organisms, and can induce pathologies 
such as chronic inflammation and autoimmune diseases, 
cardiovascular disease, neurodegenerative diseases, and 
type II diabetes.21 Persistent inflammation is also an important 
underlying condition that aids tumor development, thus 
suggesting a potential role for NF-κB in tumorigenesis.22,23 
Accordingly, the NF-κB family of proteins is frequently 
implicated in cancer particularly since the Rel homology 
domain within these TFs is homologous to the viral oncogene, 
v-Rel, from the avian reticuloendotheliosis virus.22–24
The role of NF-κB in cancer
NF-κB proteins mediate proliferation, growth, and apoptosis. 
Mutations leading to aberrant activation of NF-κB have 
thus been implicated in various cancers.3,22–25 Indeed, many 
cancers, in particular melanomas, multiple myeloma, various 
types of leukemia, and B and T-cell lymphomas, are associ-
ated with the aberrant activation of NF-κB.25,26 This is in part 
due to the characteristic NF-κB pro-inflammatory response, 
but inhibition of apoptosis and promotion of metastasis and 
cell proliferation also play vital roles. NF-κB acts to inhibit 
apoptosis, a key hallmark of cancer, downstream of growth 
factor signaling such as epidermal growth factor (EGF).27 
Here, activation of epidermal growth factor-receptor (EGFR) 
recruits phosphatidylinositide 3-kinase (PI3K) to the plasma 
membrane which in turn induces the de novo synthesis of 
phosphatidylinositol [3, 4, 5]-triphosphate; (PI[3,4,5]P3). 
This activates protein kinase B (AKT/PKB) with the help 
of phosphoinositide-dependent kinase-1 (PDK1) and mam-
malian target of rapamycin complex 2 (mTORC2).28 AKT 
has been suggested to activate NF-κB via IKK, resulting in 
the transcription of pro-survival genes, which prevent the 
death of cancer cells, particularly when EGFR or mTOR 
are constitutively activated due to mutation.26,29,30 Mutations 
leading to the activation of K-ras in the context of INK4a/
ARF deficiency in mice lead to pancreatic cancer by persis-
tent activation of the Notch and NF-κB signaling pathways.31 
NF-κB can also be activated by hypoxia, which has been 
implicated in the promotion of angiogenesis for sustaining 
the growth of cancer cells.32 Moreover, NF-κB has been 
shown to contribute to initiation, promotion, and progression 
of tumorigenesis through its role in apoptosis, inflammation, 
and regulating matrix metalloproteinase-9 as well as inducing 
the epithelial to mesenchymal transition (EMT) via TWIST1 
and SNAI1.33–37
Although it had been postulated that NF-κB can also 
function as a tumor suppressor for a number of years, through 
for example, its pro-apoptotic activities,38 recent studies 
have now revealed a new facet of this behavior through the 
induction of a stable cell growth arrest, otherwise known as 
cellular senescence.
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Figure 3 Schematic illustration of the pathways linking NF-κB to cellular senescence, cancer, and aging.
Notes: Inflammation, DNA damage, and oxidative/oncogenic stress all lead to the activation of iKKα/iKKβ resulting in the activation of NF-κB. NF-κB can inhibit tumorigenesis 
and promote aging by inducing a senescence growth arrest and SASP. Alternatively, depending upon the signal, NF-κB may promote tumorigenesis by activating cell cycle 
progression, blocking apoptosis, and inducing SASP for example.
Abbreviations: ATM, ataxia telangiectasia mutated kinase; CiP, cyclin dependent kinase interacting protein; CDK, cyclin dependent kinase; CycD, cyclin D; DNA, 
deoxyribonucleic acid; eGFR, epidermal growth factor receptor; FOXO, forkhead box; iGF1R, insulin like growth factor 1 receptor; HMGB1, high mobility group protein B1; 
iKK, ikB kinase; iL, interleukin; iR, insulin receptor; MAPK, mitogen activated protein kinase; miRNA, micro ribonucleic acid; NeMO, NF-kappa B essential modulator, also 
known as inhibitor of nuclear factor kappa B kinase subunit gamma; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; Pi3K, phosphatidylinositol 3-kinase; PiP, 
phosphatidylinositol phosphate; pRB, retinoblastoma protein; SASP, senescence associated secretory phenotype; TAB, transforming growth factor-beta activated kinase binding 
protein; TAK, transforming growth factor-beta activated kinase; TGF, transforming growth factor; TNF, tumor necrosis factor; TRAFS, TNF receptor associated factors.
Introduction to cellular senescence, 
aging, and cancer
Somatic cells typically undergo a finite number of divisions 
before they irreversibly exit the cell cycle; this replicative 
limit is known as the Hayflick limit.39 Cellular senescence 
occurs in response to a variety of intrinsic and extrinsic 
stimuli, some of which include: progressive telomere 
shortening/uncapping, oncogene activation, aberrant DNA 
damage, oxidative stress, and other forms of genotoxic and 
non-genotoxic stresses.40–42 Senescence results in cellular 
hypertrophy and a pro-inflammatory and hyper-secretory 
phenotype. Senescent cells show resistance to apoptosis, are 
metabolically active, and remain viable for long periods of 
time.43 They also exhibit dramatic changes in morphology 
whereby cells become enlarged and flattened, making the 
senescent phenotype unique, easy to distinguish, and thus 
easy to detect.44 Senescent cells may also be distinguished by 
the upregulation or increased activity of various biomarkers 
such as senescence-associated-β-galactosidase, plasminogen 
activator inhibitor (PAI)-1, fibronectin, p53, and the cyclin 
dependent kinase inhibitors p21CIP1/WAF1/SDI1 and p16INK4a.45
Although there are different categories of cellular 
senescence, such as replicative senescence or premature 
senescence, both trigger a DNA-damage response, resulting 
in activation of the p53 and the retinoblastoma protein (pRB) 
tumor suppressors.46 P53 initiates senescence by activating 
the expression of the cyclin dependent kinase inhibitor, 
p21CIP1/WAF1/SDI1, which in turn inhibits the cyclin E/cyclin 
dependent kinase 2 (CDK2) complex of the cell cycle. This 
prevents the phosphorylation and deactivation of the pRB 
family of pocket proteins permitting hypophosphorylated 
pRB to complex with the E2F family of heterodimeric TFs.47 
In turn, pRB recruits histone deacetylases and remodeling 
factors to E2F responsive promoters, thereby inhibiting 
E2F-dependent S-phase gene expression.40,48 In response to 
non-genotoxic stress, the pRB pathway is activated indepen-
dently of p53 via the upregulation of p16INK4A, which acts to 
inhibit cyclinD-CDK4/6 complexes from phosphorylating 
pRB.44 Equally, p53 may also induce senescence by alterna-
tive pathways, as it is a master TF that regulates a plethora of 
target genes affecting physiological pathways important for 
senescence such as E2F7, which promotes the repression of 
several E2F target genes.49 However, many of the pathways 
downstream of p53 still remain poorly defined (Figure 3).
Senescence can lead to organismal aging by compro-
mising tissue renewal, repair, and regeneration via the 
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accumulation of non-dividing cells and secretion of an array 
of inflammatory cytokines, chemokines, and matrix metallo-
proteinases.43,50 Accumulation of post-mitotic cells also leads 
to the depletion of stem and progenitor cell populations via 
the disruption of stem-cell homeostasis, thereby preventing 
the replenishment of old or damaged cells.51 Removal of 
senescent cells attenuates age-related tissue dysfunction and 
extends healthy lifespan. However, senescence can also act as 
a potent tumor suppressor mechanism through the removal 
of genetically unstable and pre-cancerous cells from the 
proliferative pool.43
Cancer is considered to be a disease of the cell cycle, 
as cancer cells lose the stringent controls normally present 
during cell cycle progression. This is often the result of 
mutations via DNA damage; such damage can also act as a 
signal for senescence and inhibition of the cell cycle, pre-
venting tumor growth. Thus senescence may act as a quality 
control mechanism for eliminating less healthy cells from 
the population, thereby maintaining genome integrity and 
appropriate cellular function.52 Indeed, the induction of pre-
mature senescence in vivo has been shown to suppress tumor 
formation via the activation of key senescence pathways.53 
Several studies suggest that senescence must first be over-
come for the initiation of cancer or maintaining the growth 
of cancer cells, which can then proliferate indefinitely; a 
key hallmark of cancer.54–56 Interestingly, chemotherapy 
using antimitotic drugs has been shown to induce cellular 
senescence in cancer cells that have evaded apoptosis.57 The 
radiotherapy response of lung cancer cells has been shown 
to be mediated through both apoptosis and senescence.58 
Hence, there has been a recent push in cancer therapeutics 
to target cellular senescence as a way of treating cancer, 
but the downstream effectors of cellular senescence are 
currently poorly defined. Moreover, vital questions remain 
to be answered about what makes this process of cell cycle 
arrest essentially irreversible and what are the players that 
underlie this stable arrest.
Role of NF-κB in promoting  
cellular senescence
The role of NF-κB in reinforcing cellular senescence is 
currently emerging and is rapidly being recognized to have 
a causal role in this growth arrest.59 Bernard and colleagues 
provided the first evidence indicating that NF-κB may 
inhibit growth by transiently overexpressing c-REL in HeLa 
cells; this led to a cell cycle arrest in all stages of the cell 
cycle, although the arrest was not demonstrated to be irre-
versible.60,61 Later studies by Hardy et al suggested a novel 
role for NF-κB in senescence growth arrest.62 They used 
cDNA microarrays to identify genes that were differentially 
expressed when conditionally immortal human mammary 
(HMF3A) fibroblasts underwent senescence, followed by 
in silico promoter analysis of the differential genes and 
electrophoretic mobility shift assays to show that NF-κB 
was activated upon senescence. Shortly after, Adler et al 
showed that NF-κB was strongly associated with and was 
required to enforce pathological aging in mice.63
Rovillain et al64 extended the Hardy et al study by using 
genome-wide expression profiling, in conjunction with inac-
tivation of the p16-pRB and p53-p21 tumor suppressor path-
ways in the conditionally immortal HMF3A fibroblasts, and 
found that 91 NF-κB downstream targets were up regulated 
upon senescence arrest; many of these targets are associated 
with the senescence associated secretory phenotype (SASP). 
Moreover, suppression of NF-κB by short hairpin ribonucleic 
acid (shRNA) silencing, or by ectopic expression of the I-κB 
super-repressor of NF-κB, abrogated senescence arrest in 
these conditionally immortal fibroblasts.64
Interestingly, silencing of the bona-fide oncoprotein DEK 
leads to upregulation of NF-κB and its associated proteins 
resulting in a G2 cell cycle block and cellular senescence in 
CaSki cervical carcinoma cells.65 Senescence is thought to 
be reinforced by the activation of cell surface bound cytokine 
interleukin (IL)-1α, which in turn activates NF-κB, as 
the expression of IL-1α in culture is one of the earliest events 
to occur after growth arrest.66,67 Freund et al have proposed 
that p38 mitogen activated protein kinase (MAPK) induces 
senescence via NF-κB activation.68  Collectively, these, as well 
as other studies, have suggested a causal role for NF-κB in 
promoting  cellular senescence.
NF-κB, DNA damage response,  
and senescence
Although it is not known how NF-κB activates senes-
cence, links have been made between the DNA damage 
response, the best-known activator of cellular senescence, 
and NF-κB activation. Inhibition of NF-κB by depletion of 
one allele of p65, or pharmacological inhibition of IKK, 
has been reported to reduce oxidative damage and stress 
whilst delaying cellular senescence in progeroid mice.69 
Further studies, in two different mouse models of accel-
erated aging, have shown that accumulation of prelamin 
A, at the nuclear lamina, triggers an ataxia telangiectasia 
mutated (ATM)- and NEMO- signaling pathway leading 
to activation of NF-κB and secretion of proinflammatory 
cytokines.70 Moreover, inhibition of NF-κB increases lon-
gevity of these mice by abrogating senescence.70 Lifespan 
extension in mice has also been recently achieved by 
OncoTargets and Therapy 2013:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1226
Mowla et al
preventing aging-related hypothalamic IKKβ and NF-κB 
activation, which normally inhibit gonadotropin-releasing 
hormone (GnRH).71 It is currently thought that genotoxic 
stress activates the NF-κB pathway, in mice, by stimulating 
Poly [ADP-ribose] polymerase 1 (PARP-1) and ATM, which 
induces the synthesis of poly adenosine diphosphate (ADP) 
ribose and the subsequent assembly of ATM and an IKKγ/
PIASγ complex that activates NF-κB.72 Furthermore, studies 
in human dermal fibroblasts have revealed crosstalk between 
p53 and NF-κB to induce cellular senescence through the 
repression of cyclin D1 as a response to ultraviolet (UV) 
light-induced DNA damage.73
Since DNA-damage can also lead to other cell fates such 
as apoptosis or quiescence through activation of the p53 and 
pRB pathways, it remains to be elucidated how cellular senes-
cence prevails over these cell fates in a particular context. As 
NF-κB has been shown in vitro and in vivo to block apoptosis 
in cancer cells, as well as normal cells, in response to DNA 
damage,74,75 it can be hypothesized that NF-κB has a role in 
committing the cell to cellular senescence by minimizing 
the choice of cell fates. Therefore, activation of ATM leads 
to a cell cycle arrest and NF-κB activation in response to 
DNA double strand breaks,75 whereas inhibition of NF-κB 
sensitizes transformed cells to apoptosis induced by ionizing 
radiation or chemotherapeutic drugs.76,77
Furthermore, inhibition of aurora kinases with MLN8054/
MLN8237 in mice with metastatic melanoma tumors led to 
suppression of tumor growth by induction of polyploidy and 
the ATM/CHK2 DNA damage response, which mediated 
senescence and a NF-κB related SASP.78 However, block-
ade of IKKβ/NF-κB leads to reversal of MLN8237-induced 
senescence and SASP.78 This suggests that targeting cellular 
senescence through NF-κB could provide a potential anti-
cancer therapy.
Senescence associated secretory 
phenotype and NF-κB
NF-κB activation has been coupled to the SASP.79 Senescent 
cells secrete a variety of inflammatory cytokines, proteases 
and growth factors such as: tumor necrosis factor (TNF)
α and IL-6, monocyte chemoattractant protein-1, matrix 
metalloproteinases, and EGFs [44]. Campisi and colleagues 
have shown that a variety of senescent-inducing stimuli 
activate p38MAPK, which in turn induces SASP, by upreg-
ulating transcriptional activity of NF-κB.68 This is also 
sufficient for SASP induction in melanoma cells.79 More-
over, Chien et al recently observed that NF-κB signaling 
controlled the appearance of SASP in H-RasV12-induced 
senescence in human skin fibroblasts, and that RELA 
was significantly enriched in the chromatin of senescent 
fibroblasts.80
NF-κB is thought to promote SASP by activating the 
expression of IL-6 and IL-8, which also contribute to rein-
forcing senescence growth arrest. Some studies suggest that 
IL-1α is also required for this activation, as silencing of IL-1α 
significantly decreased the senescence associated secretion 
of IL-6/8 by reducing the DNA binding activity of NF-κB 
and CCAAT-enhancer-binding protein beta (c/EBPβ).81 Cells 
undergoing oncogene induced senescence also secrete mul-
tiple CXCR2-binding chemokines, in a NF-κB and c/EBPβ 
dependent manner.82 However, the occurrence of SASP in 
vivo, in response to NF-κB, remains to be elucidated and the 
role of SASP in senescence growth arrest is controversial, as 
SASP can also promote cancer.
SASP and cancer
Adding a further layer of complexity to the NF-κB friend/
foe dilemma, senescence also has a role in tumor promo-
tion through the secretion of inflammatory, growth promot-
ing and remodeling factors that senescent cells secrete as 
SASP.67 Such factors promote the EMT, metastasis, and 
proliferation of neighboring cells. Metalloproteases, secreted 
as SASP, lead to the degradation of the basement membrane 
surrounding tissues, further promoting tumor metastasis. 
Hence, SASP creates a microenvironment that favors malig-
nancy in neighboring cells when it is persistent, as is the case 
in aging cells.83 Interestingly, it has recently been shown that 
cultured medium, derived from senescent cells, is sufficient 
to induce the growth of cancer cells, but this was inhibited 
by the anti-diabetic drug, metformin, which inhibits SASP 
and downregulates NF-κB induced transcription.84 However, 
when SASP was inhibited by low levels of metformin, growth 
arrest still occurred, suggesting that other downstream targets 
are also important for the growth arrest. Interestingly, drug 
induced senescent cells have been shown to increase the pro-
liferation of bystander cells in vitro but did not significantly 
alter tumor growth in vivo.85
SASP can also reinforce growth arrest and protect against 
cancer by activating the immune response, inducing the 
clearance of damaged and pre-cancerous cells.86 Accordingly, 
senescence may have evolved as an example of antagonistic 
pleiotrophy, since it provides beneficial traits during the 
reproductive age of an individual (tumor suppression via 
growth arrest), but causes deleterious effects later on in life 
(aging and cancer via SASP).43 We thus hypothesize that 
the dual role of NF-κB in tumor promotion and suppression 
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may, in part, be due to its promotion of SASP (summarized 
in Figure 3).
Conclusion
The NF-κB family of transcription factors has gained 
considerable attention due to their roles in various stress-
induced pathways. Central to this is the role of NF-κB in 
both promoting cancer and acting as a tumor suppressor via 
the induction of cellular senescence. We have summarized 
the evidence indicating a role of NF-κB in both of these 
pathologies and suggest that depending upon the biological 
context, type, and intensity of the signal, NF-κB can indeed 
promote senescence arrest in somatic cells. We propose that 
these opposing decisions are determined by a combination 
of differential NF-κB subunit expression and modification 
in combination with crosstalk from other signaling pathways 
such as p53. Future studies, aimed at providing a greater 
understanding of the preferential expression of different 
NF-κB subunits in a particular context, and their engage-
ment with different signaling pathways, will shed light on 
the opposing roles of NF-κB in cancer.
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